James H. Doroshow, M.D., FACP, became the Deputy Director for Clinical and Translational Research of the National Cancer Institute in 2011, where he served as the Director of the Division of Cancer Treatment and Diagnosis from 2004 to 2011. He continues to pursue his own research program as a Senior Investigator in the Laboratory of Molecular Pharmacology of the NCI’s intramural Center for Cancer Research. From 1983 to 2004, Dr. Doroshow was the Chairman of the City of Hope Comprehensive Cancer Center’s Department of Medical Oncology and Therapeutics Research. From the time of his first research grant in 1980, Dr. Doroshow was continuously funded by the NCI until he moved to the NIH in 2004. He is the author of over 350 full-length publications in the areas of anthracycline antibiotic molecular pharmacology, the role of oxidant stress in tumor cell signal transduction, and novel therapeutic approaches to solid tumors. Dr. Doroshow served from 1990-1992 as Chairman of the National Institutes of Health Experimental Therapeutics II Study Section, from 1995-2001 as a member of the Subspecialty Board on Medical Oncology of the American Board of Internal Medicine, from 1999-2000 as Chairman of NCI’s Scientific Review Group A-Cancer Centers, and from 2004-2007 as a member of the FDA’s Oncologic Drugs Advisory Committee. Dr. Doroshow chaired the NCI’s Clinical Trials Working Group from 2004-2005 that developed a comprehensive set of initiatives to restructure the national cancer clinical trials enterprise; he also chaired the NCI’s Operational Efficiency Working Group from 2008-2010 that developed standards to significantly shorten the timeline for cancer clinical trial implementation across all of NCI’s clinical trials platforms. He is currently a member of the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine of the National Academies of Science.Dr. Doroshow received his bachelor’s degree, magna cum laude, from Harvard College in 1969 and his medical degree alpha omega alpha from Harvard Medical School in 1973. After completing an internship and residency in Internal Medicine at the Massachusetts General Hospital in Boston, he spent three years (1975-78) performing his fellowship in Medical Oncology in the Medicine and Clinical Pharmacology Branches of the NCI.